Abu Dhabi Creates Life Sciences Giant

In a move designed to solidify Abu Dhabi's position in the life sciences sector, the emirate's investment and holding company, ADQ, announced the formation of Arcera. This newly established global holding company, headquartered in Abu Dhabi, aims to become a major force in the international life sciences market.

Arcera's creation consolidates ADQ's existing assets within the life sciences field. This strategic move brings together holdings in Switzerland's Acino International, Turkey's Birgi Mefar Group, and Egypt's Amoun Pharmaceutical Company under one umbrella. The new entity boasts a portfolio of over 2,000 branded medicines across various therapeutic areas, addressing a wide range of acute and chronic conditions.

With its sights set on ambitious growth targets, Arcera plans to double its revenue within the next five years. This growth will be fueled by strategic acquisitions in key global markets and the forging of international partnerships. The company also possesses a robust manufacturing and packaging base, with seven sites strategically located across the UAE, Switzerland, Ukraine, Estonia, South Africa, Turkey, and Egypt.

The establishment of Arcera aligns perfectly with Abu Dhabi's 2030 Healthcare Life Sciences Vision. This long-term vision seeks to transform the emirate into a hub for medical innovation and research. Arcera's global presence will further bolster the UAE's aspirations to become a leader in science and technology.

The announcement of Arcera was met with enthusiasm from industry experts. Analysts believe the creation of this new life sciences powerhouse will not only benefit Abu Dhabi but also contribute to advancements in global healthcare. By leveraging its combined expertise and resources, Arcera is poised to play a significant role in developing and delivering innovative healthcare solutions across the globe.

Previous Article Next Article